 <!--program start-->
        <div class="col-md-12 mt-2">
            <div class="tab" role="tabpanel">
                <!-- Nav tabs -->
              <div class="row">
                  <div class="col-md-9 col-sm-12">
                    <ul class="nav nav-tabs" role="tablist">
                    <li role="presentation" class="active"><a href="<?php echo base_url();?>program/day1" aria-controls="home" role="tab" data-toggle="tab">Day 1, Friday 19<sup>th</sup> April 2019</a></li>
                    <li role="presentation" class="active"><a href="<?php echo base_url();?>program/day2" aria-controls="profile" role="tab" data-toggle="tab">Day 2, Saturday 20<sup>th</sup> April 2019</a></li>
                     <li role="presentation"><a href="<?php echo base_url();?>program/day3" aria-controls="profile" role="tab" data-toggle="tab">Day 3, Sunday 21<sup>st</sup> April 2019</a></li>
                </ul>
                <!-- Tab panes -->
                  </div>
                  <div class="col-md-3 col-sm-12">
                    <a href="<?php echo base_url();?>assets/conference/Conference_Brochure.pdf" target="_blank"><button class="btn btn-info text-center">Download pdf</button></a>
                  </div>
                </div>

  <div class="row">
    <div class="col-md-4 s12 m8 pricing-tabs center">
      <a href="<?php echo base_url(); ?>program/d3halla"><div class="col s12 m4 tab-item">
        <h1 class="text-center">HALL A</h1>
      </div></a>
    </div>
    <div class="col-md-4 s12 m8 pricing-tabs center">
     <a href="<?php echo base_url(); ?>program/d3hallb"><div class="col s12 m4 tab-item active">
        <h1 class="text-center">HALL B</h1>
      </div></a>
    </div>
    </div>


                <!-- Tab panes -->
                <div class="tab-content tabs">
                    <div role="tabpanel" class="tab-pane  in active" id="Section1">
                      <!--session 1 start-->
                      <div class="section-tab">
                        <h3><span class="year">08.00 - 08.45</span> Session 13: QUIZ for PG students</h3>
                      </div>
                      <!--session 1 end-->
                      <!-- session 2 start-->
                      <div class="section-tab">
                        <h3><span class="year">08.45 - 09.45</span> Session 14: PREVENTIVE and PRIMARY CARE</h3>
                        <span class="time">08.45 - 08.55</span>
                        <div class="title-border">
                          <p><i class="fa fa-check-square-o" aria-hidden="true"></i> <strong> Abstract 1</strong>: Linking cervicovaginal immune signatures, HPV and microbiota composition in cervical carcinogenesis in non-Hispanic and Hispanic women.</p>
                          <h6>Laniewski P, et al., Sci Rep 2018; 8: 7593</h6>

                          <p><i class="fa fa-check-square-o" aria-hidden="true"></i> <strong> Abstract 2</strong>: Relationship between the Cervical Microbiome, HIV Status and Precancerous Lesions.</p>
                          <h6>Klein C, et al.,MBio. 2019 Feb 19;10(1)</h6>
                         <p><i class="fa fa-check-square-o" aria-hidden="true"></i> <strong> Abstract 3</strong>:  Hand-to-genital and genital-to-genital transmission of human papillomaviruses between male and female sexual partners (HITCH): a prospective cohort study. </p>
                          <h6>Talía Malagón et al., Lancet Infect Dis 2019</h6>

                         <p><i class="fa fa-check-square-o" aria-hidden="true"></i> <strong> Abstract 4</strong>: Five-Year Risk of Cervical Precancer Following p16/Ki-67 Dual-Stain Triage of HPV-PositiveWomen.</p>
                          <h6>Megan A. Clarke, et al., JAMA Oncol. 2019;5(2):181-186</h6>

                         <p><i class="fa fa-check-square-o" aria-hidden="true"></i> <strong> Abstract 5</strong>: Performance of human papillomavirus testing on self-collected versus clinician-collected samples for the detection of cervical intraepithelial neoplasia of grade 2 or worse: a randomised, paired screen-positive, non-inferiority trial. </p>
                          <h6>Nicole J Polman, et al.,Lancet Oncol. 2019 Feb;20(2):229-238</h6>
                        </div>



                          <span class="time">08.55 - 09.05</span>
                        <div class="title-border">
                          <p><i class="fa fa-check-square-o" aria-hidden="true"></i> <strong> Abstract 6</strong>:Trends in Human Papillomavirus Vaccine Types 16 and 18 in Cervical Precancers, 2008–2014</p>
                          <h6>Nancy M. McClun, et al.,Cancer Epidemiol Biomarkers Prev. 2019 Mar;28(3):602-609</h6>

                          <p><i class="fa fa-check-square-o" aria-hidden="true"></i> <strong> Abstract 7</strong>: Screening for Cervical Cancer: US Preventive Services Task Force Recommendation Statement.</p>
                          <h6>Curry SJ, et al.,JAMA. 2018 Aug 21;320(7):674-686</h6>

                         <p><i class="fa fa-check-square-o" aria-hidden="true"></i> <strong> Abstract 8</strong>:  Screening for Cervical Cancer With High-Risk Human Papillomavirus Testing: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.</p>
                          <h6>Melnikow J, et al., JAMA. 2018 Aug 21;320(7):687-705</h6>
                        </div>


                         <span class="time">09.05 - 09.15</span>
                        <div class="title-border">
                          <p><i class="fa fa-check-square-o" aria-hidden="true"></i> <strong> Abstract 9</strong>: Association Between Polycystic Ovary Syndrome and Cancer Risk. </p>
                          <h6>Yin W1, et al.,JAMA Oncol. 2019 Jan 1;5(1):106-107</h6>

                          <p><i class="fa fa-check-square-o" aria-hidden="true"></i> <strong> Abstract 10</strong>: Association between contemporary hormonal contraception and ovarian cancer in women of reproductive age in Denmark: prospective, nationwide cohort study.</p>
                          <h6>Lisa Iversen, et al.,BMJ. 2018 Sep 26;362:k3609</h6>


                         <p><i class="fa fa-check-square-o" aria-hidden="true"></i> <strong> Abstract 11</strong>: Risk of Malignant Ovarian Cancer Based on Ultrasonography Findings in a Large Unselected Population. </p>
                          <h6>Smith-Bindman R, et al.,JAMA Intern Med. 2019 Jan 1;179(1):71-77</h6>

                         <p><i class="fa fa-check-square-o" aria-hidden="true"></i> <strong> Abstract 12</strong>:  Risk of complications in patients with conservatively managed ovarian tumours (IOTA5): a 2-year interim analysis of a multicentre, prospective, cohort study. </p>
                          <h6>Froyman W, et al.,Lancet Oncol. 2019 Mar;20(3):448-458</h6>

                         <p><i class="fa fa-check-square-o" aria-hidden="true"></i> <strong> Abstract 13</strong>: US Preventive Services Task Force Recommendation Statement. Screening for Ovarian Cancer</p>
                          <h6>JAMA. 2018; 319(6):588-594</h6>
                        </div>
                      <h4 class="panel-discussion"><span class="year">09.15 - 09.45</span> Panel Discussion</h4>
                      </div>
                      <!--session 2 end-->
                      <!-- session 3 start-->
                      <div class="section-tab">
                        <h3><span class="year">09.45 - 11.15</span>Session 15: OVARIAN CANCER</h3>

                         <span class="time">09.45 - 10.00</span>
                        <div class="title-border">
                          <p><i class="fa fa-check-square-o" aria-hidden="true"></i> <strong> Abstract 1</strong>: Correlation between Surgeon's assessment and radiographic evaluation of residual disease in women with advanced stage ovarian cancer reported to have undergone optimal surgical cytoreduction: An NRG Oncology/Gynecologic Oncology Group study.</p>
                          <h6>Ramez N. Eskander, et al.,Gynecol Oncol. 2018 Jun;149(3):525-530</h6>

                          <p><i class="fa fa-check-square-o" aria-hidden="true"></i> <strong> Abstract 2</strong>: A phase III randomized controlled trial of secondary surgical cytoreduction (SSC) followed by platinum-based combination chemotherapy (PBC), with or without bevacizumab (B) in platinum-sensitive, recurrent ovarian cancer (PSOC): A NRG Oncology/Gynecologic Oncology Group (GOG) study.
                          </p>
                          <h6>Robert L Coleman, et al.,ASCO 2018,JCO.2018.36.15_suppl.5501</h6>

                         <p><i class="fa fa-check-square-o" aria-hidden="true"></i> <strong> Abstract 3</strong>:  A Randomized Trial of Lymphadenectomy in Patients with Advanced Ovarian Neoplasms. </p>
                          <h6>Philipp Harter, et al.,N Engl J Med. 2019 Feb 28;380(9):822-832</h6>

                         <p><i class="fa fa-check-square-o" aria-hidden="true"></i> <strong> Abstract 4</strong>:  Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer. </p>
                          <h6>Willemien J. van Drier January 18, 2018. N Engl J Med 2018; 378:230-240</h6>

                         <p><i class="fa fa-check-square-o" aria-hidden="true"></i> <strong> Abstract 5</strong>:  Morbidity and Mortality Rates Following Cytoreductive Surgery Combined With Hyperthermic Intraperitoneal Chemotherapy Compared With Other High-Risk Surgical Oncology Procedures.</p>
                          <h6>Foster JM,et al.,JAMA Netw Open. 2019 Jan 4;2(1):e186847</h6>
                        </div>

                        
                        <span class="time">10.00 - 10.10</span>
                        <div class="title-border">
                          <p><i class="fa fa-check-square-o" aria-hidden="true"></i> <strong> Abstract 6</strong>:Survival analyses from a randomized trial of primary debulking surgery versus neoadjuvant chemotherapy for advanced epithelial ovarian cancer with high tumor load (SCORPION trial)</p>
                          <h6>Anna Fagotti, et al.,JCO 36, no. 15_suppl (May 20 2018) 5516-5516</h6>

                          <p><i class="fa fa-check-square-o" aria-hidden="true"></i> <strong> Abstract 7</strong>: Comparison of survival between upfront primary debulking surgery versus neoadjuvant chemotherapy for stage III/IV ovarian, tubal and peritoneal cancers in phase III randomized trial: JCOG0602</p>
                          <h6>Takachi Onda,et al.,JCO 36, no. 15_suppl (May 20 2018) 5500-5500</h6>

                         <p><i class="fa fa-check-square-o" aria-hidden="true"></i> <strong> Abstract 8</strong>:  Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials.</p>
                          <h6>Ignace Vergote, et al.,Lancet Oncol. 2018 Dec;19(12):1680-1687</h6>
                        </div>


                         <span class="time">10.10 - 10.20</span>
                        <div class="title-border">
                          <p><i class="fa fa-check-square-o" aria-hidden="true"></i> <strong> Abstract 9</strong>:AGO OVAR 2.21. A prospective randomized Phase III trial of Carboplatin / Gemcitabine / Bevacizumab vs. Carboplatin / Pegylated Liposomal Doxorubicin / Bevacizumab in patients with platinum-sensitive recurrent ovarian cancer. An ENGOT / GCIG Trial.ESMO 2018,Abstract 933O</p>
                          <h6>J. Pfisterer, et al.,Annals of Oncology (2018) 29 (suppl_8): viii332-viii358</h6>

                          <p><i class="fa fa-check-square-o" aria-hidden="true"></i> <strong> Abstract 10</strong>: Alisertib in Combination With Weekly Paclitaxel in Patients With Advanced Breast Cancer or Recurrent Ovarian Cancer: A Randomized Clinical Trial. </p>
                          <h6>Falchook G, et al.,JAMA Oncol. 2019 Jan 1;5(1):e183773</h6>

                         <p><i class="fa fa-check-square-o" aria-hidden="true"></i> <strong> Abstract 11</strong>:  Paclitaxel With and Without Pazopanib for Persistent or Recurrent OvarianCancer: A Randomized Clinical Trial.</p>
                          <h6>Debra L., et al.,JAMA Oncol. 2018; 4(2):196-202</h6>

                            <p><i class="fa fa-check-square-o" aria-hidden="true"></i> <strong> Abstract 12</strong>:  Tumor Treating Fields in combination with paclitaxel in recurrent ovarian carcinoma: Results of the INNOVATE pilot study. </p>
                          <h6>Vergote I, et al.,Gynecol Oncol. 2018 Sep;150(3):471-477</h6>
                        </div>


                        <span class="time">10.20 - 10.30</span>
                        <div class="title-border">
                          <p><i class="fa fa-check-square-o" aria-hidden="true"></i> <strong> Abstract 13</strong>Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.</p>
                          <h6>Moore K, et al., N Engl J Med. 2018 Dec 27;379(26):2495-2505</h6>

                          <p><i class="fa fa-check-square-o" aria-hidden="true"></i> <strong> Abstract 14</strong>: Health-related quality of life and patient-centred outcomes with olaparib maintenance after chemotherapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT Ov-21): a placebo-controlled, phase 3 randomised trial  </p>
                          <h6>Michael Friedlander, et al.,Lancet Oncol. 2018 Aug;19(8):1126-1134</h6>

                         <p><i class="fa fa-check-square-o" aria-hidden="true"></i> <strong> Abstract 15</strong>:  Quality of life in patients with recurrent ovarian cancer treated with niraparib versus placebo (ENGOT-OV16/NOVA): results from a double-blind, phase 3, randomised controlled trial. Lancet Oncol 2018. </p>
                          <h6>Amit M Oza, et al.,Lancet Oncol. 2018 Aug;19(8):1117-1125</h6>

                            <p><i class="fa fa-check-square-o" aria-hidden="true"></i> <strong> Abstract 16</strong>:  TOPACIO/Keynote-162 (NCT02657889): A phase 1/2 study of niraparib + pembrolizumab in patients (pts) with advanced triple-negative breast cancer or recurrent ovarian cancer (ROC)—Results from ROC cohort. </p>
                          <h6>Panagiotis A,et al., ASCO 2018,Abstract 106.JCO 36, no. 15_suppl (May 20 2018) 106-106</h6>
                        </div>

                         <span class="time">10.30 - 10.40</span>
                        <div class="title-border">
                          <p><i class="fa fa-check-square-o" aria-hidden="true"></i> <strong> Abstract 17</strong>BRCA Challenge: BRCA Exchange as a global resource for variants in BRCA1 and BRCA2.</p>
                          <h6>Cline MS, et al.,PLoS Genet. 2018 Dec 26;14(12):e1007752.</h6>

                          <p><i class="fa fa-check-square-o" aria-hidden="true"></i> <strong> Abstract 18</strong>:Accurate classification of BRCA1 variants with saturation genome editing. </p>
                          <h6>Gregory M. Findlay, et al.,Nature. 2018 Oct;562(7726):217-222</h6>

                         <p><i class="fa fa-check-square-o" aria-hidden="true"></i> <strong> Abstract 19</strong>: Molecular profiling of ovarian germ cell tumors. </p>
                          <h6>M. Stasenko, et al.,SGO 2018,Abstract 42</h6>

          
                        </div>
                        <h4 class="panel-discussion"><span class="year">10.40 - 11.15</span> Panel Discussion</h4>
                        <h4 class="break-sessions"><span class="year">11.15 - 11.30</span>TEA BREAK</h4>
                   
                      </div>
                      <!--session 3 end-->
                      <!-- session 4 start-->
                      <div class="section-tab">
                        <h3><span class="year">11.30 - 12.35</span>Session 16: UTERINE CANCER</h3>
                        
                          <span class="time">11.30 - 11.45</span>
                        <div class="title-border">
                          <p><i class="fa fa-check-square-o" aria-hidden="true"></i> <strong> Abstract 1</strong>:Association of Endometrial Cancer Risk With Postmenopausal Bleeding in Women: A Systematic Review and Meta-analysis.</p>
                          <h6>Clarke MA,et al., JAMA Intern Med. 2018 Sep 1;178(9):1210-1222</h6>

                          <p><i class="fa fa-check-square-o" aria-hidden="true"></i> <strong> Abstract 2</strong>:Evaluation of liquid from the Papanicolaou test and other liquid biopsies for the detection of endometrial and ovarian cancers.
                          </p>
                          <h6>Wang Y,et al.,Sci Transl Med. 2018 Mar 21;10(433)</h6>

                         <p><i class="fa fa-check-square-o" aria-hidden="true"></i> <strong> Abstract 3</strong>:  Near-infrared fluorescence for detection of sentinel lymph nodes in women with cervical and uterine cancers (FILM): a randomised, phase 3, multicentre, non-inferiority trial. </p>
                          <h6>Frumovitz M, et al.,Lancet Oncol. 2018 Oct;19(10):1394-1403</h6>

                         <p><i class="fa fa-check-square-o" aria-hidden="true"></i> <strong> Abstract 4</strong>:  Sentinel lymph node (SLN) isolated tumor cells (ITCs) in otherwise stage I/II endometrioid endometrial cancer: To treat or not to treat? </p>
                          <h6>F.J. Backes, et al. Gynecologic Oncology 149:7-8.June 2018 (SGO 2018)</h6>

                         <p><i class="fa fa-check-square-o" aria-hidden="true"></i> <strong> Abstract 5</strong>:  GOG 244, the lymphedema and gynecologic cancer (LEG) study: Incidence and risk factors in newly diagnosed patients.</p>
                          <h6>J.W. Carlsona, et al.,Abstract 11,SGO 2018</h6>
                        </div>

                     
                        <span class="time">11.45 - 11.55</span>
                        <div class="title-border">
                          <p><i class="fa fa-check-square-o" aria-hidden="true"></i> <strong> Abstract 6</strong>:Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial. PORTEC study group.</p>
                          <h6>de Boer SM,et al., Lancet Oncol. 2018 Mar;19(3):295-309</h6>

                          <p><i class="fa fa-check-square-o" aria-hidden="true"></i> <strong> Abstract 7</strong>:Patient-Reported Toxicity During Pelvic Intensity-Modulated Radiation Therapy: NRG Oncology-RTOG 1203.
                          </p>
                          <h6>Klopp AH,et al.,J Clin Oncol. 2018 Aug 20;36(24):2538-2544</h6>
                        </div>
                      
                        <span class="time">11.55 - 12.05</span>
                        <div class="title-border">
                          <p><i class="fa fa-check-square-o" aria-hidden="true"></i> <strong> Abstract 8</strong>:Single-course methotrexate and single-course combined methotrexate–dactinomycin: A phase III randomized controlled clinical trial in treatment of low-risk gestational trophoblastic neoplasm.</p>
                          <h6>L. Chena, et al., Gynecologic Oncology 149:20.June 2018.(SGO 2018)</h6>

                          <p><i class="fa fa-check-square-o" aria-hidden="true"></i> <strong> Abstract 9</strong>:The impact of uterine re-curettage on the number of chemotherapy courses in treatment of post molar gestational trophoblastic neoplasia: A randomized controlled study
                          </p>
                          <h6>R. Hemidaa, et al.,Abstract 41,SGO 2018</h6>
                          
                           <p><i class="fa fa-check-square-o" aria-hidden="true"></i> <strong> Abstract 10</strong>:TROPHIMMUN, a 2 cohort phase II trial of the anti-PD-L1 monoclonal antibody avelumab in chemo-resistant gestational trophoblastic neoplasia (GTN) patients: preliminary outcomes in cohort A. L
                          </p>
                          <h6>You BM.et al.,BA35, ESMO 2018</h6>
                      </div>
                       <h4 class="panel-discussion"><span class="year">12.05 - 12.35</span>Panel Discussion</h4>
                    </div>
                      <!--session 4 end-->
                      <!-- session 5 start-->
                      <div class="section-tab">
                        <h3><span class="year">12.35 - 13.50</span>Session 17: CERVICAL CANCER</h3>
                         <span class="time">12.35 - 12.45</span>
                        <div class="title-border">
                          <p><i class="fa fa-check-square-o" aria-hidden="true"></i> <strong> Abstract 1</strong>:Revised FIGO staging for carcinoma of the cervix uteri.</p>
                          <h6>Bhatla Net al.,Int J Gynaecol Obstet. 2019 Apr;145(1):129-135.</h6>

                          <p><i class="fa fa-check-square-o" aria-hidden="true"></i> <strong> Abstract 2</strong>:High-risk human papillomavirus status and prognosis in invasive cervical cancer: A nationwide cohort study.
                          </p>
                          <h6>Lei J,,et al.,PLoS Med. 2018 Oct 1;15(10)</h6>

                         <p><i class="fa fa-check-square-o" aria-hidden="true"></i> <strong> Abstract 3</strong>:Circulating Human Papillomavirus DNA as a Biomarker of Response in Patients With Locally Advanced Cervical Cancer Treated With Definitive Chemoradiation. </p>
                          <h6>Kathy Han,et al.,JCO Precision Oncology - published online September 13, 2018</h6>
                        </div> 


                        <span class="time">12.45 - 12.55</span>
                        <div class="title-border">
                          <p><i class="fa fa-check-square-o" aria-hidden="true"></i> <strong> Abstract 4</strong>:LACC trial Minimally Invasive versus Abdominal Radical Hysterectomy for Cervical Cancer. November 15, 2018 N Engl J Med 2018. (To also integrate the LACC Abstract IGCS c/o AM & LACC Abstract IGCS c/o AM in the same presentation)</p>
                          <h6>Pedro T. Ramirez, et al.,N Engl J Med 2018; 379:1895-1904</h6>

                          <p><i class="fa fa-check-square-o" aria-hidden="true"></i> <strong> Abstract 5</strong>:Survival after minimally invasive radical hysterectomy for early-stage cervical cancer.
                          </p>
                          <h6>Melamed A,et al.,N Engl J Med 2018;379:1905-1914</h6>

                         <p><i class="fa fa-check-square-o" aria-hidden="true"></i> <strong> Abstract 6</strong>:Outcomes and costs of open, laparoscopic and laparoscopic radical hysterectomy for stage 1B1 cervical cancer. </p>
                          <h6>Margul DJ, et al.,Journal of Clinical Oncology 36, no. 15_suppl (May 20 2018) 5502-5502.</h6>


                        <p><i class="fa fa-check-square-o" aria-hidden="true"></i> <strong> Abstract 7</strong>:Comparison of survival outcomes between minimally invasive surgery and conventional open surgery for radical hysterectomy as primary treatment in patients with stage IB1-IIA2 cervical cancer. </p>
                          <h6>Kim SI, et al.,Gynecol Oncol. 2019 Jan 12.</h6>
                        </div> 

                        <span class="time">12.55 - 13.10</span>
                        <div class="title-border">
                          <p><i class="fa fa-check-square-o" aria-hidden="true"></i> <strong> Abstract 8</strong>:Neoadjuvant Chemotherapy Followed by Radical Surgery Versus Concomitant Chemotherapy and Radiotherapy in Patients With Stage IB2, IIA, or IIB Squamous Cervical Cancer: A Randomized Controlled Trial.</p>
                          <h6>Gupta S, et al. J Clin Oncol. 2018 Jun 1;36(16):1548-1555</h6>

                          <p><i class="fa fa-check-square-o" aria-hidden="true"></i> <strong> Abstract 9</strong>:Cisplatin Chemoradiotherapy vs Radiotherapy in FIGO Stage IIIB Squamous Cell Carcinoma of the Uterine Cervix: A Randomized Clinical Trial
                          </p>
                          <h6>Shrivastava S et al.,JAMA Oncol. 2018 Apr 1;4(4):506-513</h6>

                         <p><i class="fa fa-check-square-o" aria-hidden="true"></i> <strong> Abstract 10</strong>:Randomized trial of adjuvant chemotherapy versus concurrent chemoradiotherapy in early-stage cervical cancer after radical surgery: A Chinese Gynecologic Oncology Group study (CSEM-002). </p>
                          <h6>D. Wenga, et al. SGO 2018</h6>


                        <p><i class="fa fa-check-square-o" aria-hidden="true"></i> <strong> Abstract 11</strong>:Association of Definitive Pelvic Radiation Therapy With Survival Among Patients With Newly Diagnosed Metastatic Cervical Cancer. </p>
                          <h6>Yuefeng Wang, et al., JAMA Oncol. 2018;4(9):1288-1291.</h6>

                         <p><i class="fa fa-check-square-o" aria-hidden="true"></i> <strong> Abstract 12</strong>:Pembrolizumab treatment of advanced cervical cancer: Updated results from the phase 2 KEYNOTE-158 study </p>
                          <h6>Hyun Cheol Chung,et al.,Journal of Clinical Oncology 36, no. 15_suppl (May 20 2018) 5522-5522</h6>
                        </div> 
                      
                          <h4 class="panel-discussion"><span class="year">13.10 - 13.50</span>Panel Discussion</h4>
                      </div>
                      <!--session 5 end-->
                      <!-- session 6 start-->
                      <div class="section-tab">
                        <h3><span class="year">13.50 - 14.10</span>Session 18: RAPID REVIEW</h3>
                        <span class="time">13.50 - 14.00</span>
                        <div class="title-border">
                          <ul>
                            <li>
                              Association of Breast and Ovarian Cancers With Predisposition Genes Identified by Large-Scale Sequencing. Lu HM, Li S, Black MH, Lee S, Hoiness R, Wu S, Mu W, Huether R, Chen J, Sridhar S, Tian Y, McFarland R, Dolinsky J, Tippin Davis B, Mexal S, Dunlop C, Elliott A. JAMA Oncol. 2018 Aug 16.

                            </li>
                            <li>
                              Oral Contraceptive Use and Risks of Cancer in the NIH-AARP Diet and Health Study. Michels KA, Brinton LA, Pfeiffer RM, Trabert B. Am J Epidemiol. 2018 Aug 1;187(8):1630-1641

                            </li>
                            <li>
                              Hormone Replacement Therapy After Oophorectomy and Breast Cancer Risk Among BRCA1 Mutation Carriers.Kotsopoulos J, Gronwald J, Karlan BY, Huzarski T, Tung N, Moller P, Armel S, Lynch HT, Senter L, Eisen A, Singer CF, Foulkes WD, Jacobson MR, Sun P, Lubinski J, Narod SA; Hereditary Breast Cancer Clinical Study Group. JAMA Oncol. 2018 Aug 1;4(8):1059-1065

                            </li>
                            <li>
                              Different menopausal hormone regimens and risk of breast cancer. Brusselaers N, Tamimi RM, Konings P, Rosner B, Adami HO, Lagergren J.Ann Oncol. 2018 Aug 1;29(8):1771-1776.

                            </li>
                          </ul>
                        </div>
                        <span class="time">14.00 - 14.10</span>
                        <div class="title-border">
                          <ul>
                            <li>
                              Oncological management and obstetric and neonatal outcomes for women diagnosed with cancer during pregnancy: a 20-year international cohort study of 1170 patients. Jorine de Haan, Magali Verheecke, Kristel Van Calsteren, Ben Van Calster, Roman G Shmakov, Mina Mhallem Gziri, and others. The Lancet Oncology, Vol. 19, No. 3, p337–346

                            </li>
                            <li>
                              Fertility Preservation in Patients With Cancer: ASCO Clinical Practice Guideline Update. Kutluk Oktay, Brittany E. Harvey, Ann H. Partridge, Gwendolyn P. Quinn, Joyce Reinecke, Hugh S. Taylor, W. Hamish Wallace, Erica T. Wang, Alison W. Loren. JCO JUL 2018
                            </li>
                            <li>
                              Outpatient Talc Administration by Indwelling Pleural Catheter for Malignant Effusion Rahul Bhatnagar, Ph.D April 5, 2018 N Engl J Med 2018; 378:1313-1322
                            </li>
                            <li>
                              Association Between Ultraprocessed Food Consumption and Risk of Mortality Among Middle-aged Adults in France. Schnabel L, Kesse-Guyot E, Allès B, Touvier M, Srour B, Hercberg S, Buscail C, Julia C. JAMA Intern Med. 2019 Feb 11.
                            </li> 
                          </ul>
                        </div>
                      
                      
                     
                          <h4 class="break-sessions"><span class="year">14.10 onwards</span>Valedictory & Vote of thanks</h4>
                      </div>
                      <!--session 6 end-->
                  

                    </div>
                </div>
            </div>
        </div>
      <!--program end-->
